From Mitokine to Therapeutic: Mitochondrial-Derived Peptides (MOTS-c, Humanin, SHLPs, and Synthetic Analogs) as Exercise Mimetics and Adjuncts in Metabolic Disease and Aging
ICME JOURNAL OF LABORATORY MEDICINE · 2026 · 7-15
DOI: 10.54646/icme.2026.14 ↗Kurz gefasst
Fachartikel in der Zeitschrift ICME JOURNAL OF LABORATORY MEDICINE, 2026. Verfasst von Riju Mathew und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Progressive mitochondrial dysfunction, insulin resistance, and sarcopenia are central pathological hallmarks of metabolic decline and biological aging. Although physical activity remains the most effective non-pharmacological intervention to restore metabolic homeostasis, substantial clinical populations—including frail older adults, bedridden patients, and individuals with severe neuromuscular or cardiovascular impairment—cannot sustain sufficient exercise. Mitochondrial-derived peptides (MDPs), including MOTS-c, Humanin, and Small Humanin-Like Peptides (SHLPs), constitute an endocrine-like mitokine network encoded within short open reading frames of mtDNA that govern systemic bioenergetics and recapitulate key physiological adaptations of physical exertion.
Objective
To systematically review and critically appraise preclinical and clinical evidence regarding the structural biogenesis, intracellular and endocrine signaling mechanisms, and therapeutic efficacy of MOTS-c, Humanin, SHLP2/3, and synthetic analogs (notably HNG and CB4211) as standalone exercise mimetics or adjunct therapies in metabolic disease, sarcopenia, and age-related functional decline.
Methods
A PRISMA 2020-compliant search was conducted across MEDLINE (PubMed), Embase, and Web of Science Core Collection from database inception through July 2026. Original investigations, clinical trials, and mechanistic translational studies evaluating exogenous MDP administration or endogenous MDP modulation were extracted and appraised for signaling targets (AMPK, AKT, PGC-1α, gp130, FPRL1, STAT3) and translational validity.
Results
MOTS-c inhibits the folate–methionine cycle, elevates ZMP, and activates AMPK at Thr172, thereby promoting insulin-independent GLUT4 translocation, PGC-1α-driven mitochondrial biogenesis, and nuclear translocation with NRF2 to engage antioxidant response elements. Humanin and its analog HNG signal through a heterotrimeric gp130/WSX-1/IL-27Rα complex and FPRL1 while sequestering BAX to suppress caspase-3/9 cleavage, mitigating skeletal muscle atrophy and endothelial dysfunction. In clinical translation, the MOTS-c analog CB4211 (NCT04123558) achieved significant ALT (−21%) and AST (−28%) reductions in Phase 1b clinical testing in MASH and obesity.
Conclusions
MDPs display robust exercise-mimetic signatures across multiple organ systems. MDPs are best conceptualized as exercise rescue agents and synergistic metabolic adjuncts for patients unable to perform sufficient physical activity.
Zitieren
APA
Mathew, R., K, J. T., & Joe, S. (2026). From Mitokine to Therapeutic: Mitochondrial-Derived Peptides (MOTS-c, Humanin, SHLPs, and Synthetic Analogs) as Exercise Mimetics and Adjuncts in Metabolic Disease and Aging. ICME JOURNAL OF LABORATORY MEDICINE, 7-15. https://doi.org/10.54646/icme.2026.14
Vancouver
Mathew R, K JT, Joe S. From Mitokine to Therapeutic: Mitochondrial-Derived Peptides (MOTS-c, Humanin, SHLPs, and Synthetic Analogs) as Exercise Mimetics and Adjuncts in Metabolic Disease and Aging. ICME JOURNAL OF LABORATORY MEDICINE. 2026:7-15. doi:10.54646/icme.2026.14
BibTeX
@article{Mathew2026,
author = {Mathew, Riju and K, Jithesh T and Joe, Sheena},
title = {From Mitokine to Therapeutic: Mitochondrial-Derived Peptides (MOTS-c, Humanin, SHLPs, and Synthetic Analogs) as Exercise Mimetics and Adjuncts in Metabolic Disease and Aging},
journal = {ICME JOURNAL OF LABORATORY MEDICINE},
year = {2026},
pages = {7--15},
doi = {10.54646/icme.2026.14}
}
EUVIMED